Lung Neoplasm Clinical Trials

62 recruitingLast updated: June 18, 2026

There are 62 actively recruiting lung neoplasm clinical trials across 29 countries. Studies span Not Applicable, Phase 2, Phase 1, Early Phase 1, Phase 3. Top locations include Shanghai, Shanghai Municipality, China, Houston, Texas, United States, Athens, Attica, Greece. Updated daily from ClinicalTrials.gov.


Lung Neoplasm Trials at a Glance

62 actively recruiting trials for lung neoplasm are listed on ClinicalTrialsFinder across 6 cities in 29 countries. The largest study group is Not Applicable with 25 trials, with the heaviest enrollment activity in Shanghai, Houston, and Athens. Lead sponsors running lung neoplasm studies include Merck Sharp & Dohme LLC, AstraZeneca, and Cancer Research UK.

Browse lung neoplasm trials by phase

Treatments under study

About Lung Neoplasm Clinical Trials

Looking for clinical trials for Lung Neoplasm? There are currently 15 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Lung Neoplasm trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Lung Neoplasm clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 62 trials

Recruiting
Phase 1

Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma

Ovarian NeoplasmsStomach NeoplasmsLung Neoplasms+5 more
National Cancer Institute (NCI)100 enrolled1 locationNCT06885697
Recruiting
Phase 1Phase 2

A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F)

Lung Neoplasm Malignant
Merck Sharp & Dohme LLC190 enrolled21 locationsNCT07286149
Recruiting
Phase 2

Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC

Non-small Cell Lung CancerLung NeoplasmsCarcinoma+6 more
Pfizer120 enrolled3 locationsNCT07489066
Recruiting
Phase 2

Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult Participants With Transformed Small Cell Lung Cancer

Lung NeoplasmsSmall Cell Lung CancerSmall Cell Lung Cancer ( SCLC )+3 more
Pfizer40 enrolled12 locationsNCT07476287
Recruiting
Not Applicable

Clinical Study of a New Treatment Model for Elderly Lung Cancer Patients

Lung NeoplasmPerioperative CareAged+2 more
Peking University People's Hospital1,000 enrolled1 locationNCT07632664
Recruiting
Phase 2

Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAKER-U01)

Lung Neoplasm Malignant
Merck Sharp & Dohme LLC60 enrolled37 locationsNCT06788912
Recruiting
Phase 2

Substudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01I/KEYMAKER-U01I)

Lung Neoplasm
Merck Sharp & Dohme LLC144 enrolled40 locationsNCT06780098
Recruiting

LUNG-ROLL: Treatment Patterns and Cost of Illness of Lung Cancer in Canada

Lung Neoplasms
AstraZeneca60,000 enrolled2 locationsNCT07143110
Recruiting

Ventilation Using Radiographic Examination: Functional Lung Imaging Techniques for the Reduction of Toxicity in Functional Avoidance Radiation Therapy

Lung Neoplasm
University of Sydney15 enrolled1 locationNCT06159660
Recruiting

DeniLA: Comprehensive Demographics and Clinical Profile of NSCLC Patients: Analyzing Guideline-Concordant Care in First-line Treatment Patterns

Lung Neoplasms
AstraZeneca200 enrolled7 locationsNCT07109154
Recruiting

3D Virtual Resection for Predicting Lung Function in VATS

Lung CancerNon-small Cell Lung CancerLung Neoplasms
National Taiwan University Hospital60 enrolled1 locationNCT07436598
Recruiting
Not Applicable

Double-Dose Third-Generation EGFR-TKI Plus Bevacizumab and Intrathecal Chemotherapy for Refractory Leptomeningeal Metastatic NSCLC: A Phase II Study

Leptomeningeal MetastasisLung Neoplasms, Non-Small Cell Lung Cancer
Second Affiliated Hospital of Nanchang University30 enrolled1 locationNCT07398599
Recruiting

Patient-derived Organoid Model and Circulating Tumor Cells for Treatment Response of Lung Cancer

Lung Neoplasm
The University of Texas Health Science Center at San Antonio150 enrolled1 locationNCT03655015
Recruiting
Not Applicable

Enhanced COPD Management in Suspected Lung Cancer Patients

Lung CarcinomaLung Cancer (Diagnosis)Pulmonary Cancer+8 more
Ditte Krag-Hansen280 enrolled1 locationNCT07543601
Recruiting
Not Applicable

Confocal Laser Endomicroscopy VERification

Lung CancerCarcinoma, Non-Small Cell LungLung Neoplasm Malignant+1 more
Amsterdam University Medical Centers (UMC), Location Academic Medical Center (AMC)208 enrolled5 locationsNCT06079970
Recruiting
Not Applicable

MDT-Based Umbrella Decision Model for Geriatric Lung Cancer Patients

Carcinoma, Non-Small Cell LungLung NeoplasmsElderly+1 more
West China Hospital2,000 enrolled1 locationNCT07509333
Recruiting
Not Applicable

Benefit of Spectral Information in Patients Suspected for Lung Cancer

Lung Neoplasm Malignant
Copenhagen University Hospital at Herlev1,000 enrolled1 locationNCT06440616
Recruiting
Not Applicable

Biomarker Platform (Virtual Nodule Clinic) for the Management of Indeterminate Pulmonary Nodules

Lung Neoplasm
Vanderbilt-Ingram Cancer Center400 enrolled5 locationsNCT06638398
Recruiting

The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study

Breast CancerLiver CancerEsophageal Cancer+35 more
UMC Utrecht8,000 enrolled18 locationsNCT04075305
Recruiting

To Conduct Multi-omics Integrated Studies in Peripheral Blood, Such as Fragment Omics, Metabolomics and Epigenetics, and Establish Non-invasive Dynamic Follow-up Monitoring Programs During Perioperative and Postoperative Periods (Observational Study)

Neoadjuvant TherapyLung NeoplasmsMinimal Residual Disease+1 more
Peking University People's Hospital100 enrolled1 locationNCT07291921